Clinical Trial Update: Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis [Phase 2]

View source ↗

Summary

A Phase 2 study of deucravacitinib for refractory dermatomyositis and juvenile dermatomyositis has been withdrawn. The trial was sponsored by the National Insti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Myositis

Drugs mentioned

• Sotyktu (Deucravacitinib)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Myositis, Dermatomyositis | Phase 2 | Status: WITHDRAWN